Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewResearchpeer-review

  3. Increased liver fat associates with severe metabolic perturbations in low birth weight men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Research output: Contribution to journalReviewResearchpeer-review

  1. Approach to the patient with glucocorticoid-induced adrenal insufficiency

    Research output: Contribution to journalReviewResearchpeer-review

  2. Sex differences in sudden cardiac death in a nationwide study of 54 028 deaths

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Latent Causes of Sudden Cardiac Arrest

    Research output: Contribution to journalReviewResearchpeer-review

  4. Severe weight loss in a hypothyroid patient as an acute presentation of autoimmune polyglandular syndrome type II

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Context: Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective.

Objective: To investigate the safety and efficacy of Tesomet (0.5 mg tesofensine/50 mg metoprolol) in adults with hypothalamic obesity.

Methods: Twenty-one adults with hypothalamic obesity (16 females) were randomized to Tesomet (0.5 mg/50 mg) or placebo for 24 weeks. Patients also received diet/lifestyle counselling. The primary endpoint was safety; secondary endpoints included measures of body weight, appetite scores, quality of life, and metabolic profile.

Results: Eighteen patients completed 24 weeks. Consent withdrawal, eligibility, and serious adverse events (SAE) unrelated to treatment resulted in dropouts. One patient experienced a Tesomet-related SAE of exacerbated pre-existing anxiety leading to treatment discontinuation. Tesomet-related adverse events were otherwise mostly mild and included sleep disturbances (Tesomet 50%, placebo 13%), dry mouth (Tesomet 43%, placebo 0%), and headache (Tesomet 36%, placebo 0%). No significant differences in heart rate or blood pressure were observed between groups. Compared to placebo, Tesomet resulted in additional mean (95% CI) weight change of -6.3% ((-11.3; -1.3); P = 0.017), increased the number of patients achieving ≥5% weight loss (Tesomet 8/13, placebo 1/8; P = 0.046), and tended to augment the reduction in waist circumference by 5.7 cm ((-0.1; 11.5); P = 0.054).

Conclusion: Tesomet was welltolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume186
Issue number6
Pages (from-to)687-700
Number of pages14
ISSN0804-4643
DOIs
Publication statusPublished - 9 May 2022

    Research areas

  • Adult, Appetite Depressants/adverse effects, Body Weight, Double-Blind Method, Female, Humans, Hypothalamic Diseases/complications, Male, Obesity/complications, Quality of Life, Weight Loss

ID: 75652238